Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
441-460 of 1,738 trials

HER2-Low Breast Cancer: Trastuzumab-Deruxtecan Study

We are studying a new treatment for patients with HER2-low breast cancer and brain metastases to see if it helps shrink tumors and improve quality of life. This trial will also look at safety and how well patients tolerate the treatment.

HER2-Low Breast Cancer with Brain Metastases1-2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesNeurologyOncology

Crohn's Disease: TAK-279 Oral Medication

We are studying a new oral treatment for people with moderately to severely active Crohn's disease. The trial aims to see if it helps improve symptoms and overall health compared to a placebo.

Crohn's Disease1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementGastroenterologyInternal Medicine

Aggressive Large B-Cell Lymphoma: Golcadomide After CAR T-Cell Therapy

We are studying whether golcadomide can improve outcomes for patients with aggressive large B-cell lymphoma after receiving CAR T-cell therapy. The trial will look at response rates and safety in those at high risk of relapse.

Aggressive Large B-Cell Lymphoma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncology

Mantle-Cell Lymphoma: Glofitamab with Venetoclax and Zanubrutinib

We are studying a new treatment combination for patients with untreated or relapsed high-risk mantle-cell lymphoma. The trial aims to see if this combination works better than Venetoclax alone.

Mantle-Cell Lymphoma>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesHematologyOncology

ALK Positive Non-Small Cell Lung Cancer: Chemotherapy Plus Lorlatinib

We are studying a combination of chemotherapy and Lorlatinib for patients with ALK positive NSCLC who have had disease progression outside the brain. The goal is to see if this treatment improves outcomes compared to past therapies.

Advanced Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesPartially RemoteOncology

Metastatic Breast Cancer: [177Lu]Lu-NeoB with Capecitabine

We are studying a new treatment combining [177Lu]Lu-NeoB and capecitabine for adults with specific metastatic breast cancer. The goal is to find the best doses and evaluate how well it works after other treatments have failed.

Metastatic Breast Cancer6-12 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyOncology

Penile Cancer: Carboplatin, Paclitaxel, and Pembrolizumab Study

We are studying a combination of chemotherapy and immunotherapy for patients with locoregionally advanced penile cancer. The goal is to see if this treatment can effectively shrink tumors before surgery and to assess its safety.

Locoregionally Advanced Penile Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyUrology

Duchenne Muscular Dystrophy: BMN 351 Treatment Study

We are testing a new treatment called BMN 351 to see if it is safe and well-tolerated in people with Duchenne Muscular Dystrophy. The study will also look at how the drug is processed in the body.

Duchenne Muscular Dystrophy>2 yearsSafety phase (I)Efficacy phase (II)>20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyOrthopedics and Traumatology

Advanced Gastric Cancer: EXL01 with Nivolumab and FOLFOX

We are studying a new treatment combination for patients with advanced gastric cancer to see if it improves response rates and safety. This trial focuses on those with a specific biomarker to better understand treatment effectiveness.

Metastatic Gastric Adenocarcinoma>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesGastroenterologyOncology

Non-Small Cell Lung Cancer: STX-721/PFL-721 Treatment

We are studying a new treatment for people with non-small cell lung cancer who have specific mutations. The goal is to see if it can improve their condition compared to standard therapies.

Non-Small Cell Lung Cancer>2 yearsSafety phase (I)Efficacy phase (II)Oncology

Spinal Muscular Atrophy: RO7204239 with Risdiplam

We are studying the safety and effectiveness of a new treatment combining RO7204239 with risdiplam for individuals with spinal muscular atrophy. This trial will help us understand how well this combination works compared to a placebo.

Spinal Muscular Atrophy (SMA)1-2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessPartially RemoteInternal MedicineNeurology

Ulcerative Colitis: TAK-279 Oral Medication

We are testing the effectiveness of TAK-279 for people with moderately to severely active ulcerative colitis. The study aims to see if it helps achieve remission and improves symptoms compared to a placebo.

Ulcerative Colitis1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementGastroenterologyInternal Medicine

Adrenomyeloneuropathy: Dimethyl Fumarate Study

We are investigating whether dimethyl fumarate can improve symptoms in patients with adrenomyeloneuropathy compared to a placebo. The trial also looks at the safety of this medication.

Adrenomyeloneuropathy>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesNeurology

Pain Relief for Kids: Fentanyl vs. Ketamine vs. Morphine

We are studying whether intranasal fentanyl or ketamine is more effective than oral morphine for reducing pain in children with limb injuries. This trial involves children aged 2 to 17 in emergency departments.

Limb InjuriesUrgency>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesInternal MedicineOtolaryngologyPediatrics

LSTA1 for Newly Diagnosed Glioblastoma Multiforme

We are studying whether adding LSTA1 to standard treatment (temozolomide) improves survival for patients with newly diagnosed GBM compared to a placebo. The trial also looks at quality of life and other important health measures.

Glioblastoma Multiforme>2 yearsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementOncology

CP-506 for Solid Tumors: A New Treatment Study

We are testing a new drug, CP-506, in patients with specific solid tumors to see how safe it is and how well it works. This study may help those with tumors that have certain genetic features or who are not responding well to current treatments.

Solid Tumors with DNA Repair Deficiencies>2 yearsSafety phase (I)Efficacy phase (II)Oncology

Recurrent Gynecological Cancers: IMGN151 Study

We are testing a new drug, IMGN151, in women with recurrent gynecological cancers to assess its safety and determine the best dose. This study aims to understand how well the drug works and its effects on patients.

Recurrent Gynecological Cancers>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGynecology and ObstetricsOncology

Severe Corneal Ulcers: NANOULCOR Treatment

We are studying an artificial cornea model for patients with severe corneal ulcers that don't respond to regular treatments. The goal is to see if it helps heal the ulcers and improves vision.

Corneal Ulcer≤3 monthsEfficacy phase (II)No PlaceboInvestigational MedicinesOphthalmology

Chronic Hepatitis B: Long-Term Study on Treatment Response

We are investigating how well previous participants of a hepatitis B treatment maintain their health over time. This study focuses on those who have stopped certain therapies and aims to understand their long-term outcomes.

Chronic Hepatitis BEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHepatologyInfectious Diseases

Liver Cancer: Fecal Microbiota Transfer Study

We are investigating whether fecal microbiota transfer can help liver cancer patients who are resistant to standard treatments. The study aims to improve immune response and overall survival.

Non-resectable Hepatocellular Carcinoma>2 yearsEfficacy phase (II)6-10 visitsStandard MedicinesHepatologyInternal MedicineOncology